In 2027 the National Institutes of Health (NIH) will cease supporting costs associated with clinical trials within career development (K) awards. NIH's working definition of clinical trials spans a wide spectrum of research activities, from early-stage pilot or feasibility studies through definitive efficacy or effectiveness trials. Understanding what types and sizes of clinical trials are currently included in K awards can inform the potential impact of this policy change on training and workforce development for future trialists.
The investigators performed a cross-sectional analysis using NIH RePORTER data to identify K01, K08, and K23 awards funded in fiscal years 2024–2025 under funding opportunity announcements (FOAs) labeled CT Required or CT Optional, restricting to awards with non-missing abstract text.
A rule-based classification scheme was applied to free-text study abstracts to categorize each award into one of five mutually exclusive trial-type categories: pilot/feasibility/proof-of-concept; efficacy/effectiveness; trial confirmed but type unclear; other (mechanistic, ancillary, or phase I/II); or no trial-specific language identified. For awards that reported an explicit sample size in the abstract, sample size values were manually verified and summarized.
Among 1,336 unique awards meeting inclusion criteria, the distribution across the five classification categories was as follows:
These results indicate that a large majority of identifiable clinical trial activity embedded in K awards represents early-stage or proof-of-concept work.
Of the 1,336 awards, 1,051 were funded under CT Required FOAs and 285 under CT Optional FOAs. Within the CT Required group, 730 awards (69.5%) were classified as pilot, feasibility, or proof-of-concept studies. The predominance of early-stage trial types within FOAs explicitly requiring clinical trials underscores that K awardees conducting trials under these announcements are frequently leading smaller, exploratory trials rather than large definitive studies.
Sample size was explicitly reported and manually verified for 273 awards (20.4% of the total sample). Among these awards with verified sample sizes:
These sample size distributions are consistent with the classification findings that most embedded clinical trials in K awards are small and early-stage.
The authors emphasize that clinical trial components of NIH K awards in fiscal years 2024–2025 were predominantly small, early-phase trials or pilot work. Given NIH's announced 2027 policy to discontinue funding trial costs for K awards, these findings raise concerns about how the policy could affect the development pathway for clinician-scientists and other early-career investigators who gain trial experience through K awards.
The analysis suggests that many K awardees currently gain hands-on experience running modestly sized trials—experience that contributes to building a pipeline of investigators equipped to design and conduct larger, definitive clinical trials in the future. The authors note that removing support for trial costs could adversely affect this scientist development pipeline, although the study itself presents descriptive data and does not model downstream workforce effects.
All data used in this analysis are publicly available through reporter.nih.gov, as stated by the authors. This work is reported as a medRxiv preprint posted September 20, 2026, and has not undergone peer review; the authors declared no competing interests and confirmed adherence to ethical and reporting guidelines.